Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$1.85 USD
+0.14 (8.19%)
Updated Oct 1, 2024 04:00 PM ET
2-Buy of 5 2
F Value A Growth F Momentum D VGM
Income Statements
Fiscal Year end for Accelerate Diagnostics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 12 | 13 | 12 | 11 | 9 |
Cost Of Goods | 10 | 9 | 12 | 7 | 5 |
Gross Profit | 3 | 3 | 0 | 4 | 4 |
Selling & Adminstrative & Depr. & Amort Expenses | 57 | 66 | 71 | 68 | 77 |
Income After Depreciation & Amortization | -54 | -63 | -72 | -64 | -73 |
Non-Operating Income | 1 | 4 | 9 | 1 | 3 |
Interest Expense | 8 | 4 | 16 | 16 | 14 |
Pretax Income | -61 | -63 | -78 | -78 | -84 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -62 | -62 | -78 | -78 | -84 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -62 | -62 | -78 | -78 | -84 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -46 | -58 | -57 | -49 | -61 |
Depreciation & Amortization (Cash Flow) | 8 | 4 | 14 | 14 | 12 |
Income After Depreciation & Amortization | -54 | -63 | -72 | -64 | -73 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 12.48 | 8.22 | 6.17 | 5.60 | 5.45 |
Diluted EPS Before Non-Recurring Items | -4.94 | -7.60 | -8.30 | -14.00 | -15.50 |
Diluted Net EPS (GAAP) | -4.94 | -7.60 | -12.60 | -14.00 | -15.50 |
Fiscal Year end for Accelerate Diagnostics, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 2.99 | 2.92 | 3.03 | 3.30 | 2.92 |
Cost Of Goods | 2.31 | 2.20 | 2.39 | 3.19 | 2.12 |
Gross Profit | 0.68 | 0.72 | 0.63 | 0.11 | 0.80 |
SG&A, R&D, and Dept/Amort Expenses | 9.28 | 10.88 | 11.37 | 14.76 | 13.38 |
Income After SG&A, R&D, and Dept/Amort Expenses | -8.60 | -10.16 | -10.74 | -14.65 | -12.58 |
Non-Operating Income | -0.39 | -1.62 | 0.42 | 17.90 | -18.02 |
Interest Expense | 2.59 | 2.45 | 2.13 | 2.21 | 1.98 |
Pretax Income | -11.59 | -14.23 | -12.44 | 1.04 | -32.58 |
Income Taxes | 0.00 | 0.00 | 0.56 | 0.13 | 0.16 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -11.59 | -14.23 | -13.00 | 0.91 | -32.74 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -11.59 | -14.23 | -13.00 | 0.91 | -32.74 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 23.06 | 19.22 | 14.61 | 14.55 | 11.01 |
Diluted EPS Before Non-Recurring Items | -0.50 | -0.88 | -0.89 | -0.92 | -2.36 |
Diluted Net EPS (GAAP) | -0.50 | -0.74 | -0.33 | 0.06 | -2.97 |